Who owns 4D Molecular Therapeutics, Inc. (FDMT)? Elite investor 13F holders
2 tracked elite investors reported holding 4D Molecular Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | 4D MOLECULAR THERAPEUTICS IN | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 8173821.00 USD | 614573.000000 | Shares | add | Original filing |
| D.E. Shaw | 4D MOLECULAR THERAPEUTICS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 589908.00 USD | 44354.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.